Lipegfilgrastim
As of the edition of 20 October 2026, Lipegfilgrastim is a protein: marketed, first approved in 2013 (EU); acts on CSF3R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Protein
- Brand name
- Lonquex
- First approved
- 25 July 2013 (EU)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- TEVA FARMACĂUTICA LTDA.; 2 holders in all
- Registered trials
- 5, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Heart and blood vessels; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF3R | Granulocyte colony-stimulating factor receptor | Q99062 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Teva | Applicant and Lead sponsor of trials | 2013 to now |